Endra Life Sciences Inc (NDRA)

Mar 31, 2025, 8:05 AM EDT - 4 days ago

ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies

Mar 31, 2025, 8:00 AM EDT - 4 days ago

ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

Nov 22, 2024, 8:00 AM EST - 4 months ago

ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

Nov 15, 2024, 9:24 AM EST - 5 months ago

ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 12, 2024, 8:00 AM EST - 5 months ago

Study Highlighting ENDRA Life Sciences' TAEUS Technology in Patients with High BMI to be Presented at AASLD's The Liver Meeting® 2024

Nov 6, 2024, 8:00 AM EST - 5 months ago

ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent

Oct 22, 2024, 8:00 AM EDT - 5 months ago

ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany

Aug 30, 2024, 8:54 AM EDT - 7 months ago

Data I/O And 2 Other Stocks Under $5 Executives Are Buying

DAIO

Aug 28, 2024, 4:17 PM EDT - 7 months ago

ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements

Aug 22, 2024, 5:54 PM EDT - 8 months ago

ENDRA Life Sciences Inc. (NDRA) Q2 2024 Earnings Call Transcript

Aug 22, 2024, 4:14 PM EDT - 8 months ago

ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 16, 2024, 8:00 AM EDT - 8 months ago

ENDRA Life Sciences Announces Reverse Stock Split

Aug 13, 2024, 4:05 PM EDT - 8 months ago

ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024

Aug 13, 2024, 8:00 AM EDT - 8 months ago

ENDRA Life Sciences Announces Leadership Changes

Aug 7, 2024, 8:00 AM EDT - 8 months ago

ENDRA Life Sciences to Report Second Quarter 2024 Financial Results on August 14

Jun 4, 2024, 9:21 AM EDT - 10 months ago

ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering

Jun 4, 2024, 9:06 AM EDT - 10 months ago

AM Best to Host Webinar on Engaging Defense Counsel Pre-Lawsuit

May 20, 2024, 8:00 AM EDT - 11 months ago

ENDRA Provides Update Following In-person Meeting with FDA

May 14, 2024, 8:30 PM EDT - 11 months ago

ENDRA Life Sciences Inc. (NDRA) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:05 PM EDT - 11 months ago

ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update

May 7, 2024, 8:00 AM EDT - 11 months ago

ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024

May 2, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents

Mar 28, 2024, 9:10 PM EDT - 1 year ago

ENDRA Life Sciences Inc. (NDRA) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 4:05 PM EDT - 1 year ago

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 21, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024

Feb 27, 2024, 8:00 AM EST - 1 year ago

ENDRA Life Sciences Installs First TAEUS System in the UK

Feb 21, 2024, 8:00 AM EST - 1 year ago

New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences' TAEUS System

Feb 14, 2024, 8:30 AM EST - 1 year ago

ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe

Nov 29, 2023, 8:00 AM EST - 1 year ago

ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology

Nov 27, 2023, 8:00 AM EST - 1 year ago

ENDRA Life Sciences to Participate in The Benchmark Company's 12th Annual Discovery One-on-One Investor Conference

Nov 14, 2023, 10:14 PM EST - 1 year ago

ENDRA Life Sciences Inc. (NDRA) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 4:05 PM EST - 1 year ago

ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 8:00 AM EST - 1 year ago

ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents

Nov 7, 2023, 4:05 PM EST - 1 year ago

ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023

Nov 6, 2023, 8:00 AM EST - 1 year ago

ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD's The Liver Meeting® 2023

Sep 7, 2023, 8:00 AM EDT - 1 year ago

Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023

Aug 30, 2023, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDA

Aug 23, 2023, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European Patents

Aug 14, 2023, 9:44 PM EDT - 1 year ago

ENDRA Life Sciences Inc. (NDRA) Q2 2023 Earnings Call Transcript

Aug 14, 2023, 4:05 PM EDT - 1 year ago

ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update

Aug 14, 2023, 1:30 PM EDT - 1 year ago

ENDRA Life Sciences Submits De Novo Request for its TAEUS® System Liver Fat Application to the U.S. FDA

Aug 1, 2023, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences to Report Second Quarter 2023 Financial Results on August 14, 2023

Jul 6, 2023, 4:45 PM EDT - 1 year ago

ENDRA Life Sciences Announces Adjournment of 2023 Annual Meeting of Stockholders to July 25, 2023

Jun 7, 2023, 8:00 AM EDT - 1 year ago

Study Highlighting ENDRA Life Sciences' TAEUS Technology to be Presented at EASL International Liver Congress 2023

May 15, 2023, 9:48 PM EDT - 2 years ago

ENDRA Life Sciences Inc. (NDRA) Q1 2023 Earnings Call Transcript

May 15, 2023, 4:05 PM EDT - 2 years ago

ENDRA Life Sciences Reports First Quarter 2023 Financial Results and Provides a Business Update

May 4, 2023, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences to Report First Quarter 2023 Financial Results on May 15, 2023

May 2, 2023, 4:01 PM EDT - 2 years ago

ENDRA Life Sciences Announces Closing of Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Securities

Apr 28, 2023, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Announces Pricing of Upsized $4.5 Million Public Offering

Mar 14, 2023, 7:31 PM EDT - 2 years ago

ENDRA Life Sciences Inc. (NDRA) Q4 2022 Earnings Call Transcript